ESH Video


December 06, 2022


3rd Translational Research Conference



Save the date: May 19-21, 2023

Berlin, Germany




Do not miss the opportunity, proceed now!



About the Conference:

Major recent advances in the knowledge of the biological underpinning of Acute Lymphoblastic Leukaemia (ALL) include the comprehensive description of B-cell precursor and T-cell ALL genomic landscapes, the identification of new potentially druggable disease subsets and the discovery of predisposing, preleukaemic events.

At the same time, the clinical management of the disease has improved in both children and adults thanks to the routine monitoring of measurable residual disease (MRD), the administration of intensified risk-adapted chemotherapy, the introduction of targeted therapies and antibodies, and the remarkable efficacy of antibody-drug conjugates (ADCs), bi-specific T-cell engager antibodies (BiTEs) and manufactured chimeric antigen receptor (CAR) T-cells.

This intense research activity has led to major improvements in patient outcome, while also providing important proofs of concept for the treatment of cancer in general. It has also made ALL
a fascinating disease to study.

The translational scientific programme of the 3rd Translational Research Conference on Acute Lymphoblastic Leukaemia is designed to provide ample time and opportunities for discussion with global authorities in the field.



Main scientific topics:


• KMT2A-rearranged ALL

• Advances in Ph-like ALL

• Revisiting specific ALL subsets

• New biological insights in ALL

• Ph-positive ALL

• Therapeutic Challenges in Childhood ALL

• Antibody-based ALL Therapies

• CAR T-cells & Stem Cell Transplantation

• Precision Medicine in ALL


Learning objectives of #ESHALL2023
Upon completion of this CME activity, participants should:


• Learn how to optimally diagnose and classify ALL by combining modern diagnosis algorithms
and early MRD monitoring for the rapid delivery of the right treatment to the right patient;
• Review conventional therapeutic options with a focus on
the role of allogeneic haemopoietic stem cell transplantation;
• Learn how to optimize the management of individual patients on
the basis of individual drug metabolism, tolerance and toxicity;
• Acquire improved knowledge of new, emerging targeted or immunologic treatments and understand how they may be combined or how they could eventually replace current conventional treatment options.


The programme will include:

Plenary Sessions - Panel Discussions - Debates

Poster Walks - Meet the Expert Sessions - Keynote lectures



Take a look at the preliminary programme of #ESHALL2023:


For more information, click here!